Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells $1,407,250.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $56.29, for a total value of $1,407,250.00. Following the sale, the chief executive officer owned 1,248,095 shares in the company, valued at $70,255,267.55. This trade represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $57.04, for a total value of $1,426,000.00.
• On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $41.50, for a total value of $1,037,500.00.
• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total transaction of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total transaction of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total transaction of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total transaction of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total transaction of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total transaction of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total transaction of $1,003,000.00.

Liquidia Stock Performance

Shares of Liquidia stock opened at $56.93 on Monday. The firm has a market capitalization of $5.06 billion, a PE ratio of 406.67 and a beta of 0.41. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $59.75. The firm’s 50-day moving average price is $39.70 and its 200 day moving average price is $36.04. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, sell-side analysts predict that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s first-quarter results beat Wall Street expectations on both earnings and revenue, reinforcing confidence that YUTREPIA is gaining commercial traction and that profitability is improving. Results: Liquidia Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts
• Positive Sentiment: Several analysts raised estimates and price targets after the earnings report, including HC Wainwright boosting near-term EPS forecasts and keeping a Buy rating with a $67 target, which supports the bullish outlook on LQDA. Liquidia (LQDA) price target increased by 22.37% to 63.24
• Positive Sentiment: Valuation-focused commentary highlighted that YUTREPIA-driven profitability and strong first-quarter performance could justify Liquidia’s recent share price strength if launch momentum continues. A Look At Liquidia (LQDA) Valuation After YUTREPIA Fueled Profitability And Strong First Quarter Results
• Positive Sentiment: Zacks noted improving earnings estimate revisions, suggesting analysts see additional upside potential for Liquidia in the near term. Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?
• Neutral Sentiment: Director Stephen Bloch sold 318,893 shares, a notable insider transaction, but it does not necessarily signal a change in the company’s operating outlook. Stephen Bloch Sells 318,893 Shares of Liquidia (NASDAQ:LQDA) Stock
• Neutral Sentiment: One analyst lowered a longer-dated EPS estimate, showing there is still some disagreement on how quickly growth can scale over time. Liquidia stock and analyst reports

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its stake in Liquidia by 63.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after purchasing an additional 22,592 shares in the last quarter. Quantinno Capital Management LP lifted its stake in Liquidia by 3.6% in the 1st quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock worth $648,000 after purchasing an additional 589 shares in the last quarter. Pale Fire Capital SE lifted its stake in Liquidia by 2.4% in the 1st quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock worth $14,657,000 after purchasing an additional 8,985 shares in the last quarter. Sei Investments Co. lifted its stake in Liquidia by 306.3% in the 1st quarter. Sei Investments Co. now owns 35,655 shares of the company’s stock worth $1,346,000 after purchasing an additional 26,879 shares in the last quarter. Finally, Swiss National Bank lifted its stake in Liquidia by 1.3% in the 1st quarter. Swiss National Bank now owns 120,400 shares of the company’s stock worth $4,544,000 after purchasing an additional 1,600 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on LQDA shares. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Oppenheimer raised their target price on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research note on Thursday, March 12th. Wells Fargo & Company raised their target price on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $49.33.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).